All In Biotech

Drug Trial Radar · NCT07112196

Visugromab in Cachexia International Trial

Adaptive, Phase 2/3, Randomized, Double-Blind Trial Investigating the Efficacy and Safety of Visugromab Versus Placebo in Patients With Cancer-associated Cachexia

Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 518 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

518

Planned (sponsor's estimate)

Start

Apr 16, 2026

Primary completion

Dec 2029

Study completion Dec 2030

Sponsor

Lead sponsor
CatalYm GmbHIndustry
Sponsor type
Industry
First posted
Aug 8, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A study of how well and safely a new drug called visugromab works in people with certain kinds of cancer (including lung and bowel cancer) and unintended weight loss known as cachexia. The main questions it aims to answer are: * Does visugromab help participants put weight back on and have a better appetite? * Does visugromab help participants move more and better? * What medical problems do participants have when taking visugromab? Researchers will compare visugromab to a placebo (a look-alike substance that contains no drug). Participants will visit the hospital or clinic once every 4 weeks to receive visugromab or placebo via a drip into a vein and to undergo checkups and tests.

Conditions

  • Cancer-associated Cachexia

Interventions

  • Visugromab (CTL-002)Drug

    High dose

  • PlaceboDrug

    IV infusion

  • Visugromab (CTL-002)Drug

    Medium dose

  • Visugromab (CTL-002)Drug

    Low dose

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in body weight at 12 weeksTime frame: 12 weeks
  2. Change from baseline in appetite at 12 weeksTime frame: 12 weeks

Locations

79 sites in 14 countries. Site status is shown where the registry gives one.

  • Eastern Connecticut Hematology & Oncology

    Norwich, Connecticut · Recruiting

  • Clermont Oncology Center

    Clermont, Florida · Recruiting

  • Mid Florida Hematology and Oncology Centers

    Orange City, Florida · Recruiting

  • Cleveland Clinic Martin Health

    Stuart, Florida · Recruiting

  • Cleveland Clinic Weston Hospital

    Weston, Florida · Recruiting

  • Augusta University Medical Center

    Augusta, Georgia · Recruiting

  • Astera Cancer Care

    East Brunswick, New Jersey · Recruiting

  • Cleveland Clinic Avon Hospital

    Avon, Ohio · Recruiting

  • Cleveland Clinic (Main Campus)

    Cleveland, Ohio · Recruiting

  • Cleveland Clinic Fairview Hospital

    Fairview, Ohio · Recruiting

  • Cleveland Clinic Hillcrest Hospital

    Mayfield Heights, Ohio · Recruiting

  • Specialized Hospital for Active Treatment in Oncology

    Haskovo, Bulgaria · Recruiting

  • Medical Centre Futuremeds Plovdiv

    Plovdiv, Bulgaria · Recruiting

  • University Multiprofile Hospital for Active Treatment Tsaritsa Yoanna-ISUL

    Sofia, Bulgaria · Recruiting

  • Complex Oncology Center - Vratsa EOOD

    Vratsa, Bulgaria · Recruiting

  • Multiscan, s.r.o., Nemocnice Horovice

    Hořovice, Czechia · Recruiting

  • Fakultni nemocnice Hradec Kralove

    Hradec Králové, Czechia · Recruiting

  • Fakultni nemocnice Olomouc

    Olomouc, Czechia · Recruiting

  • Vseobecna fakultni nemocnice v Praze

    Prague, Czechia · Recruiting

  • Fakultni nemocnice v Motole

    Prague, Czechia · Recruiting

  • CHRU de Brest - Hopital Morvan

    Brest, France · Recruiting

  • AP-HP Hôpital Henri Mondor

    Créteil, France · Recruiting

  • Léon Bérard Center (Centre Léon Bérard)

    Lyon, France · Recruiting

  • HCL Centre Hospitalier Lyon Sud

    Lyon, France · Recruiting

  • AP-HP Hopital Cochin

    Paris, France · Recruiting

  • Centre Paul Strauss

    Strasbourg, France · Recruiting

  • Johanniter Krankenhaus Bonn

    Bonn, Germany · Recruiting

  • University Hospital Carl Gustav Carus Dresden (Universitätsklinikum Carl Gustav Carus Dresden)

    Dresden, Germany · Recruiting

  • LungenClinic Grosshansdorf GmbH

    Großhansdorf, Germany · Recruiting

  • Universitaetsmedizin der Johannes Gutenberg - Universitaet Mainz

    Mainz, Germany · Recruiting

  • Muenchen Klinik Neuperlach

    München, Germany · Recruiting

  • St Vincent's University Hospital

    Dublin, Ireland · Recruiting

  • Centro Riferimento Oncologico - Aviano

    Aviano, Italy · Recruiting

  • ASST degli Spedali Civili di Brescia

    Brescia, Italy · Recruiting

  • Azienda Ospedaliero-Universitaria di Ferrara-Arcispedale Sant'Anna

    Ferrara, Italy · Recruiting

  • IRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori - IRST S.r.l.

    Meldola, Italy · Recruiting

  • Centro Ricerche Cliniche di Verona

    Verona, Italy · Recruiting

  • Dijklander Ziekenhuis - Locatie Hoorn

    Hoorn, Netherlands · Recruiting

  • Haukeland University Hospital

    Bergen, Norway · Recruiting

  • Sorlandet sykehus HF - Kristiansand

    Kristiansand, Norway · Recruiting

Showing 40 of 79 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.